These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 1593098)

  • 21. Vancomycin resistance.
    Hastings JG
    J Med Microbiol; 1997 Jun; 46(6):449-51. PubMed ID: 9379472
    [No Abstract]   [Full Text] [Related]  

  • 22. Avoparcin, a glycopeptide used in animal foods: antimicrobial spectrum and potency tested against human isolates from the United States.
    Cormican MG; Erwin ME; Jones RN
    Diagn Microbiol Infect Dis; 1997 Dec; 29(4):241-8. PubMed ID: 9458981
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Vancomycin resistance in Gram-positive bacteria].
    Fernández-Roblas R; Soriano F
    Enferm Infecc Microbiol Clin; 1991 Feb; 9(2):69-71. PubMed ID: 1854852
    [No Abstract]   [Full Text] [Related]  

  • 24. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives.
    Cafini F; Aguilar L; González N; Giménez MJ; Torrico M; Alou L; Sevillano D; Vallejo P; Prieto J
    J Antimicrob Chemother; 2007 Jun; 59(6):1185-9. PubMed ID: 17412725
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae.
    Patel R; Rouse MS; Piper KE; Steckelberg JM
    Diagn Microbiol Infect Dis; 1999 Jun; 34(2):119-22. PubMed ID: 10354862
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The specter of glycopeptide resistance: current trends and future considerations.
    Moellering RC
    Am J Med; 1998 May; 104(5A):3S-6S. PubMed ID: 9684651
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world performance of a microarray-based rapid diagnostic for Gram-positive bloodstream infections and potential utility for antimicrobial stewardship.
    Aitken SL; Hemmige VS; Koo HL; Vuong NN; Lasco TM; Garey KW
    Diagn Microbiol Infect Dis; 2015 Jan; 81(1):4-8. PubMed ID: 25445120
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [To discuss the vancomycin-resistant staphylococcus aureus and vancomycin-resistant enterococcus from laboratory view].
    Chen MJ; Xu YC
    Zhonghua Yi Xue Za Zhi; 2006 Apr; 86(15):1009-10. PubMed ID: 16784699
    [No Abstract]   [Full Text] [Related]  

  • 29. In vitro activity of teicoplanin and vancomycin against gram-positive bacteria from human clinical and veterinary sources.
    Jensen KT; Schønheyder H; Pers C; Thomsen VF
    APMIS; 1992 Jun; 100(6):543-52. PubMed ID: 1535201
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Mechanism of antimicrobial resistance in Gram-positive bacteria and its therapeutic tactic].
    Wang F
    Zhonghua Yi Xue Za Zhi; 1998 Mar; 78(3):236-8. PubMed ID: 10923541
    [No Abstract]   [Full Text] [Related]  

  • 31. Antibacterial efficacy of nisin against multidrug-resistant Gram-positive pathogens.
    Severina E; Severin A; Tomasz A
    J Antimicrob Chemother; 1998 Mar; 41(3):341-7. PubMed ID: 9578160
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resistant gram-positive organisms.
    Schaberg DR
    Ann Emerg Med; 1994 Sep; 24(3):462-4. PubMed ID: 8080144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Very resistant enterococci].
    Piédrola Angulo G
    An R Acad Nac Med (Madr); 1998; 115(2):499-517. PubMed ID: 9882836
    [No Abstract]   [Full Text] [Related]  

  • 34. Overview of resistant gram-positive pathogens in the surgical patient.
    Rapp RP
    Surg Infect (Larchmt); 2000; 1(1):39-47. PubMed ID: 12594908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The tigecycline evaluation and surveillance trial; assessment of the activity of tigecycline and other selected antibiotics against gram-positive and gram-negative pathogens from France collected between 2004 and 2016.
    Decousser JW; Woerther PL; Soussy CJ; Fines-Guyon M; Dowzicky MJ
    Antimicrob Resist Infect Control; 2018; 7():68. PubMed ID: 29876099
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CDC releases draft of plan for controlling vancomycin resistance in hospitals.
    Am J Hosp Pharm; 1994 Aug; 51(15):1846,9. PubMed ID: 7942919
    [No Abstract]   [Full Text] [Related]  

  • 37. [Analysis of the pathogenic characteristics of 162 severely burned patients with bloodstream infection].
    Gong YL; Yang ZC; Yin SP; Liu MX; Zhang C; Luo XQ; Peng YZ
    Zhonghua Shao Shang Za Zhi; 2016 Sep; 32(9):529-35. PubMed ID: 27647068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms of action of newer antibiotics for Gram-positive pathogens.
    Hancock RE
    Lancet Infect Dis; 2005 Apr; 5(4):209-18. PubMed ID: 15792738
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emergence of heterogeneous intermediate vancomycin resistance in Staphylococcus aureus isolates in the Düsseldorf area.
    Geisel R; Schmitz FJ; Thomas L; Berns G; Zetsche O; Ulrich B; Fluit AC; Labischinsky H; Witte W
    J Antimicrob Chemother; 1999 Jun; 43(6):846-8. PubMed ID: 10404328
    [No Abstract]   [Full Text] [Related]  

  • 40. Vancomycin-resistant enterococci.
    Moellering RC
    Clin Infect Dis; 1998 May; 26(5):1196-9. PubMed ID: 9597252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.